- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Submit PSUR data: CDSCO Panel Tells Shilpa on additional indication of Rheumatoid Arthritis drug Adalimumab
New Delhi: In response to the proposal presented by the drug major Shilpa for the extrapolation of indications for Adalimumab 100mg/mL approved in India for the indication of Rheumatoid Arthritis (RA) in adult patients, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has recommended the firm to submit periodic safety update report (PSUR) data for the first six months for consideration of approval for the additional indications.
This came after the firm presented the proposal for extrapolation of indications in line with the innovator-approved indications for Adalimumab 100mg/mL approved in India for the indication of Rheumatoid Arthritis (RA) in adult patients.
The committee noted that the firm has recently launched the drug product in the market and has not yet submitted the first PSUR.
Adalimumab injection products are in a class of medications called tumor necrosis factor (TNF) inhibitors. They work by blocking the action of TNF, a substance in the body that causes inflammation.
Adalimumab is a type of drug known as a biological therapy. In rheumatoid arthritis and some other conditions, too much of a protein called TNF is produced in the body. This causes inflammation, pain, and damage to your joints.
Adalimumab is the first fully human recombinant immunoglobulin G1 monoclonal antibody that binds and neutralizes soluble and membrane-bound tumor necrosis factor (TNF) so that it cannot interact with p55 and p75 cell-surface TNF receptors.
At the recent SEC meeting for analgesic and rheumatology held on 8th and 9th November 2023, the expert panel reviewed the proposal for extrapolation of indications in line with the innovator-approved indications for Adalimumab 100mg/mL approved in India for the indication of Rheumatoid Arthritis (RA) in adult patients presented by drug major Shilpa.
After detailed deliberation, the committee recommended that the firm should submit PSUR data for the first six months for consideration of approval for the additional indications.
Also Read:Ajanta Pharma Gets CDSCO Panel Nod To Study Antihypertensive FDC
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751